2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

ACCF : American College of Cardiology Foundation ACCP : American College of Chest Physicians ACS : acute coronary syndrome ACT : Atrial arrhythmia Conversion Trial ADONIS : American–Australian–African trial with DronedarONe In atrial fibrillation or flutter for the maintenance of Sinus rhythm AF : atrial fibrillation AHA : American Heart Association ANDROMEDA : ANtiarrhythmic trial with DROnedarone in Moderate-to-severe congestive heart failure Evaluating morbidity DecreAse APHRS : Asia Pacific Heart Rhythm Society aPTT : activated partial thromboplastin time ARB : angiotensin-receptor blocker ARISTOTLE : Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation ATHENA : A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter ATRIA : AnTicoagulation and Risk factors In Atrial fibrillation AVERROES : Apixaban VErsus acetylsalicylic acid (ASA) to Reduce the Rate Of Embolic Stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment AVRO : A prospective, randomized, double-blind, Active-controlled, superiority study of Vernakalant vs. amiodarone in Recent Onset atrial fibrillation b.i.d : bis in die (twice daily) b.p.m. : beats per minute CABANA : Catheter ABlation vs . ANtiarrhythmic drug therapy for Atrial fibrillation CABG : coronary artery bypass graft CAP : Continued Access to Protect AF CHA2DS2-VASc : Congestive heart failure or left ventricular dysfunction Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female) CHADS2 : Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke (doubled) CI : confidence interval CRAFT : Controlled Randomized Atrial Fibrillation Trial CrCl : creatinine clearance DAFNE : Dronedarone Atrial FibrillatioN study after Electrical cardioversion DIONYSOS : Randomized Double blind trIal to evaluate efficacy and safety of drOnedarone (400 mg b.i.d.) vs . amiodaroNe (600 mg q.d. for 28 daYS, then 200 mg qd thereafter) for at least 6 mOnths for the maintenance of Sinus rhythm in patients with atrial fibrillation EAST : Early treatment of Atrial fibrillation for Stroke prevention Trial EHRA : European Heart Rhythm Association ECG : electrocardiogram EMA : European Medicines Agency ERATO : Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation EURIDIS : EURopean trial In atrial fibrillation or flutter patients receiving Dronedarone for the maIntenance of Sinus rhythm FAST : atrial Fibrillation catheter Ablation vs . Surgical ablation Treatment FDA : Food and Drug Administration Flec-SL : Flecainide Short-Long trial HAS-BLED : Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly HF-PEF : heart failure with preserved ejection fraction HF-REF : heart failure with reduced ejection fraction HR : hazard ratio HRS : Heart Rhythm Society ICH : intracranial haemorrhage INR : international normalized ratio i.v. : intravenous J-RHYTHM : Japanese RHYTHM management trial for atrial fibrillation LAA : left atrial appendage LoE : level of evidence LVEF : left ventricular ejection fraction MANTRA-PAF : Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation NICE : National Institute for Health and Clinical Excellence NOAC : novel oral anticoagulant NSAID : non-steroidal anti-inflammatory drug NYHA : New York Heart Association OAC : oral anticoagulant or oral anticoagulation o.d. : omni die (every day) PALLAS : Permanent Atrial fibriLLAtion outcome Study using dronedarone on top of standard therapy PCI : percutaneous coronary intervention PREVAIL : Prospective Randomized EVAluation of the LAA closure device In patients with atrial fibrillation v s. Long-term warfarin therapy PROTECT AF : WATCHMAN LAA system for embolic PROTECTion in patients with Atrial Fibrillation PT : prothrombin time RAAFT : Radio frequency Ablation Atrial Fibrillation Trial RE-LY : Randomized Evaluation of Long-term anticoagulant therapY with dabigatran etexilate ROCKET-AF : Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in atrial fibrillation RRR : relative risk reduction TE : thromboembolism TIA : transient ischaemic attack t.i.d. : ter in die (three times daily) TOE : transoesophageal echocardiogram TTR : time in therapeutic range VKA : vitamin K antagonist Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on …

[1]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.

[2]  E. Aliot,et al.  Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. , 2007, The New England journal of medicine.

[3]  J. Halperin,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.

[4]  K. Peter,et al.  New oral anticoagulant drugs in cardiovascular disease , 2010, Thrombosis and Haemostasis.

[5]  Hakan Oral,et al.  Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. , 2002, Journal of the American College of Cardiology.

[6]  Mario Baldi,et al.  Radiofrequency Catheter Ablation and Antiarrhythmic Drug Therapy: A Prospective, Randomized, 4-Year Follow-Up Trial: The APAF Study , 2011, Circulation. Arrhythmia and electrophysiology.

[7]  S. Mouly,et al.  Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. , 2006, Archives of internal medicine.

[8]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[9]  T. Chao,et al.  CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. , 2011, Journal of the American College of Cardiology.

[10]  D. Singer,et al.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.

[11]  G. Lip,et al.  Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. , 2012, Journal of the American College of Cardiology.

[12]  D. Atar,et al.  Dronedarone in high-risk permanent atrial fibrillation. , 2011, The New England journal of medicine.

[13]  Geoffrey Lee,et al.  Low Risk of Major Complications Associated With Pulmonary Vein Antral Isolation for Atrial Fibrillation: Results of 500 Consecutive Ablation Procedures in Patients With Low Prevalence of Structural Heart Disease From a Single Center , 2010, Journal of cardiovascular electrophysiology.

[14]  Deepak L. Bhatt,et al.  Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.

[15]  J. Hartikainen,et al.  Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. , 2012, The New England journal of medicine.

[16]  A. Camm,et al.  Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[17]  G. Lip,et al.  Use of the CHA2DS2-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation , 2012, Circulation.

[18]  J. Cox.  Cardiac Surgery for Arrhythmias , 2004, Pacing and clinical electrophysiology : PACE.

[19]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[20]  G. Lip,et al.  Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice , 2012, Thrombosis and Haemostasis.

[21]  S. Sullivan,et al.  Interventions for the treatment of atrial fibrillation: a systematic literature review and meta-analysis. , 2013, International journal of cardiology.

[22]  S. Connolly,et al.  Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.

[23]  Yutao Guo,et al.  Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. , 2012, Journal of the American College of Cardiology.

[24]  G. Karthikeyan,et al.  The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe? , 2010, Thrombosis and Haemostasis.

[25]  E. Toft,et al.  Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial , 2009, Circulation. Arrhythmia and electrophysiology.

[26]  H. Tanner,et al.  Catheter ablation of atrial fibrillation as first-line therapy--a single-centre experience. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[27]  L. Køber,et al.  Excessive Supraventricular Ectopic Activity and Increased Risk of Atrial Fibrillation and Stroke , 2010, Circulation.

[28]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[29]  Jun Zhu,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[30]  Adrian V. Hernández,et al.  Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. , 2012, Archives of internal medicine.

[31]  G. Lip,et al.  Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation , 2012, Circulation. Arrhythmia and electrophysiology.

[32]  J. Plumb,et al.  Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. , 2009, Thrombosis research.

[33]  P. Neužil,et al.  PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[34]  C. Hammerstingl,et al.  The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation , 2012, Thrombosis and Haemostasis.

[35]  G. Lip,et al.  What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation? , 2012, The journal of the Royal College of Physicians of Edinburgh.

[36]  A. Camm,et al.  Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[37]  Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. , 1998, Archives of internal medicine.

[38]  S. Yusuf,et al.  Newly identified events in the RE-LY trial. , 2010, The New England journal of medicine.

[39]  S. Yusuf,et al.  Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial , 2011, Circulation.

[40]  S. Mittal,et al.  Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up? , 2012, Heart rhythm.

[41]  Andreas Metzner,et al.  Long-Term Results of Catheter Ablation in Paroxysmal Atrial Fibrillation: Lessons From a 5-Year Follow-Up , 2010, Circulation.

[42]  Gregory Y H Lip,et al.  Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data , 2008, Thrombosis and Haemostasis.

[43]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Journal of the American College of Cardiology.

[44]  A. Capucci,et al.  Improving Stroke Risk Stratification Using the CHADS2 and CHA2DS2-VASc Risk Scores in Patients With Paroxysmal Atrial Fibrillation by Continuous Arrhythmia Burden Monitoring , 2011, Stroke.

[45]  G. Breithardt,et al.  Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[46]  J. Dogné,et al.  Impact of dabigatran on a large panel of routine or specific coagulation assays , 2012, Thrombosis and Haemostasis.

[47]  李永军,et al.  Atrial Fibrillation , 1999 .

[48]  A. Camm,et al.  Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation: A Phase 3, Randomized, Placebo-Controlled Trial , 2008, Circulation.

[49]  S. Borzak,et al.  Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. , 2001, Progress in cardiovascular diseases.

[50]  Dhanunjaya R. Lakkireddy,et al.  Periprocedural Stroke and Management of Major Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The Impact of Periprocedural Therapeutic International Normalized Ratio , 2010, Circulation.

[51]  G. Breithardt,et al.  Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial , 2012, The Lancet.

[52]  Paul J. Wang,et al.  Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. , 2012, Journal of the American College of Cardiology.

[53]  J. Brachmann,et al.  Atrial Fibrillation Ablation in Patients with Therapeutic International Normalized Ratios , 2009, Pacing and clinical electrophysiology : PACE.

[54]  A. Camm,et al.  Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease. , 2013, International journal of cardiology.

[55]  N. Sattar,et al.  Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. , 2012, Archives of internal medicine.

[56]  David Keane,et al.  2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[57]  A. Natale,et al.  Pulmonary Vein Antrum Isolation for Atrial Fibrillation on Therapeutic Coumadin: Special Considerations , 2010, Journal of cardiovascular electrophysiology.

[58]  Dhanunjaya R. Lakkireddy,et al.  Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. , 2012, Journal of the American College of Cardiology.

[59]  M. Graber,et al.  Rivaroxaban vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. , 2012, American family physician.

[60]  Independent predictors of stroke in patients with atrial fibrillation , 2007, Neurology.

[61]  P. Weeke,et al.  Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort , 2011, Journal of thrombosis and haemostasis : JTH.

[62]  G. Lip,et al.  Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real world' anticoagulated atrial fibrillation population. , 2012 .

[63]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[64]  G. Lip,et al.  Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? , 2010, American Journal of Medicine.

[65]  G. Lip,et al.  Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score ? , 2012 .

[66]  Michel Haïssaguerre,et al.  Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. , 2011, Journal of the American College of Cardiology.

[67]  G. Lip,et al.  Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe , 2011, Thrombosis and Haemostasis.

[68]  Matthew Wright,et al.  Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? , 2011, Journal of the American College of Cardiology.

[69]  A. Shenker,et al.  Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay , 2010, Thrombosis and Haemostasis.

[70]  L. Køber,et al.  Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. , 2012, The American journal of medicine.

[71]  P. Kowey,et al.  Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. , 2010, JAMA.

[72]  K. Channer,et al.  A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). , 2007, Age and ageing.

[73]  J. Le Heuzey,et al.  A Short‐Term, Randomized, Double‐Blind, Parallel‐Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study , 2010, Journal of cardiovascular electrophysiology.

[74]  R. Hunter,et al.  Catheter Ablation for Atrial Fibrillation on Uninterrupted Warfarin: Can It Be Done Without Echo Guidance? , 2011, Journal of cardiovascular electrophysiology.

[75]  G. Lip,et al.  Ischaemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[76]  Burr Hall,et al.  Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. , 2010, JAMA.

[77]  G. Breithardt,et al.  Oral anticoagulation use by patients with atrial fibrillation in Germany , 2012, Thrombosis and Haemostasis.

[78]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[79]  B. Dimitrov,et al.  Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke , 2011, Thrombosis and Haemostasis.

[80]  G. Breithardt,et al.  Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options , 2011, Thrombosis and Haemostasis.

[81]  V. Budhraja.  The net clinical benefit of warfarin anticoagulation in atrial fibrillation. , 2010, Annals of internal medicine.

[82]  S. Connolly,et al.  Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective , 2011, Thrombosis and Haemostasis.

[83]  Salim Yusuf,et al.  Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial , 2011, Annals of Internal Medicine.

[84]  P. Kowey,et al.  Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. , 1998, Journal of the American College of Cardiology.

[85]  Laurent Pison,et al.  Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. , 2012, Journal of the American College of Cardiology.

[86]  D. Lane,et al.  A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice , 2011, Journal of thrombosis and haemostasis : JTH.

[87]  M. Santini,et al.  n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[88]  Andrea Natale,et al.  Percutaneous Closure of the Left Atrial Appendage. , 2012, Cardiac electrophysiology clinics.

[89]  S. Connolly,et al.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. , 2011, The Canadian journal of cardiology.

[90]  Salim Yusuf,et al.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial , 2010, The Lancet.

[91]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Heart rhythm.

[92]  F. Gaita,et al.  Incidence of Silent Cerebral Thromboembolic Lesions After Atrial Fibrillation Ablation May Change According to Technology Used: Comparison of Irrigated Radiofrequency, Multipolar Nonirrigated Catheter and Cryoballoon , 2011, Journal of cardiovascular electrophysiology.

[93]  R. P. Zhu,et al.  Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation , 2011, Annals of Internal Medicine.

[94]  W. Stevenson,et al.  Effect of Therapeutic INR on Activated Clotting Times, Heparin Dosage, and Bleeding Risk During Ablation of Atrial Fibrillation , 2011, Journal of cardiovascular electrophysiology.

[95]  J. Dunning,et al.  Best evidence topic - Cardiac general Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? , 2010 .

[96]  J. Brugada,et al.  Atrial Fibrillation Catheter Ablation Versus Surgical Ablation Treatment (FAST): A 2-Center Randomized Clinical Trial , 2012, Circulation.

[97]  Lian-Yu Lin,et al.  Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-- a nation wide database analysis. , 2011, Atherosclerosis.

[98]  E. Hylek,et al.  Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation , 2006, Stroke.

[99]  G. Lip,et al.  Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study , 2012, BMJ : British Medical Journal.

[100]  Saibal Kar,et al.  Safety of Percutaneous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry , 2011, Circulation.

[101]  I. Stiell,et al.  A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. , 2010, American heart journal.

[102]  Stephan Willems,et al.  Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[103]  S. Connolly,et al.  Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Lne Treatment of Symptomatic Atrial Fibrillation: (RAAFT 2): a Randomized Trial , 2012 .

[104]  R. de Caterina,et al.  Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable , 2011, Annals of Internal Medicine.

[105]  J. McMurray,et al.  Increased mortality after dronedarone therapy for severe heart failure. , 2008, The New England journal of medicine.

[106]  B. Gage,et al.  Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation , 2010, Circulation.

[107]  Munir Pirmohamed,et al.  Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses , 2011, BMJ : British Medical Journal.

[108]  G. Lip,et al.  Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. , 2012, Chest.

[109]  L. Epstein,et al.  Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin. , 2011, Heart rhythm.

[110]  A. Capucci,et al.  Dronedarone for prevention of atrial fibrillation: a dose-ranging study. , 2003, European heart journal.

[111]  G. Lip.  The role of aspirin for stroke prevention in atrial fibrillation , 2011, Nature Reviews Cardiology.

[112]  A. Banerjee,et al.  Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project , 2012, European Journal of Heart Failure.

[113]  V. Hasselblad,et al.  Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. , 2009, Journal of the American College of Cardiology.

[114]  Matthew R. Reynolds,et al.  Treatment of Atrial Fibrillation With Antiarrhythmic Drugs or Radiofrequency Ablation: Two Systematic Literature Reviews and Meta-Analyses , 2009, Circulation. Arrhythmia and electrophysiology.

[115]  Elia Biganzoli,et al.  Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation. Arrhythmia and electrophysiology.

[116]  A. Capucci,et al.  A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. , 2011, Journal of the American College of Cardiology.

[117]  E. Aliot,et al.  Rationale and current perspective for early rhythm control therapy in atrial fibrillation , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[118]  Deepak L. Bhatt,et al.  Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting , 2011, Thrombosis and Haemostasis.

[119]  G. Lip,et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.

[120]  G. Hindricks,et al.  ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[121]  G. Hindricks,et al.  Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[122]  A. Tosetto,et al.  Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). , 2011, Thrombosis and haemostasis.

[123]  J Raftery,et al.  A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. , 2005, Health technology assessment.

[124]  John Camm,et al.  Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[125]  J. Tolstrup,et al.  Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.

[126]  J. Halperin,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[127]  A. Waldo.  Early Recurrences After Atrial Fibrillation Ablation: Prognostic Value and Effect of Early Reablation , 2009 .

[128]  S. Connolly.  Evidence-based analysis of amiodarone efficacy and safety. , 1999, Circulation.

[129]  G. Lip,et al.  Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. , 2013, Journal of the American College of Cardiology.

[130]  M. Ezekowitz,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Journal of the American College of Cardiology.

[131]  J. Plumb,et al.  Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[132]  Mkaya Mwamburi,et al.  Systematic Review and Meta-analysis of the Efficacy of Cardioversion by Vernakalant and Comparators in Patients with Atrial Fibrillation , 2012, Cardiovascular Drugs and Therapy.

[133]  Mårten Rosenqvist,et al.  Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. , 2012, European heart journal.

[134]  Gregory Y H Lip,et al.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.

[135]  Rimm,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.

[136]  E. Abu-Assi,et al.  Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. , 2013, International journal of cardiology.

[137]  S. Yusuf,et al.  Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range , 2008, Circulation.

[138]  C. Samama,et al.  Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. , 2011, Archives of cardiovascular diseases.

[139]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[140]  A. Camm,et al.  Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[141]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[142]  A. Waldo.  Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study , 2009 .

[143]  M. Hirai,et al.  Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[144]  G. Lip,et al.  New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. , 2012, Journal of the American College of Cardiology.

[145]  D. Singer,et al.  Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. , 2011, European heart journal.

[146]  R. de Caterina,et al.  Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. , 2010, European heart journal.

[147]  G. Breithardt,et al.  Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions , 2011, Thrombosis and Haemostasis.

[148]  E. Toft,et al.  Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. , 2010, The American journal of cardiology.

[149]  S. Yusuf,et al.  Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial , 2012, Circulation.

[150]  K. Ylitalo,et al.  Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[151]  E. Antman,et al.  Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.

[152]  G. Lip.  Stroke in atrial fibrillation: epidemiology and thromboprophylaxis , 2011, Journal of thrombosis and haemostasis : JTH.

[153]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[154]  J. Kalman,et al.  Pulmonary Vein Antral Isolation for Paroxysmal Atrial Fibrillation: Results from Long‐Term Follow‐Up , 2010, Journal of cardiovascular electrophysiology.

[155]  N. G. Silveri,et al.  Efficacy and Safety of Vernakalant in Recent‐Onset Atrial Fibrillation After the European Medicines Agency Approval: Systematic Review and Meta‐Analysis , 2012, Journal of clinical pharmacology.

[156]  S. Yusuf,et al.  Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion , 2010, Circulation.

[157]  Mark A. Wood,et al.  Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation , 1996 .

[158]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[159]  D. Singer,et al.  Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators , 2009, Stroke.

[160]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[161]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[162]  P. Kirchhof,et al.  Bleeding risk assessment and management in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[163]  S. Hohnloser,et al.  Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials , 2010, Journal of cardiovascular pharmacology and therapeutics.

[164]  Jennifer G. Robinson,et al.  ACCF/AHA TASK FORCE MEMBERS , 2013 .

[165]  A. Banerjee,et al.  Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study , 2011, Thrombosis and Haemostasis.

[166]  P. Kirchhof,et al.  Left Atrial Catheter Ablation and Ischemic Stroke , 2012, Stroke.

[167]  M. Domanski,et al.  Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study , 2004, Circulation.

[168]  Bernhard Meier,et al.  Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[169]  D. Lin,et al.  Long-Term Outcome After Successful Catheter Ablation of Atrial Fibrillation , 2010, Circulation. Arrhythmia and electrophysiology.

[170]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[171]  J. Olesen,et al.  The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study , 2012, Thrombosis and Haemostasis.

[172]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[173]  D. Desilvey.  Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation: the ACTIVE W trial. , 2006, The American journal of geriatric cardiology.

[174]  G. Lip,et al.  Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. , 2011, Journal of the American College of Cardiology.

[175]  J Clémenty,et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 1998, The New England journal of medicine.

[176]  Nick Freemantle,et al.  Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[177]  W. Saliba,et al.  Catheter ablation for atrial fibrillation. , 2011, The New England journal of medicine.

[178]  J. Masjuán,et al.  Safety and Outcomes following Thrombolytic Treatment in Stroke Patients Who Had Received Prior Treatment with Anticoagulants , 2012, Cerebrovascular Diseases.

[179]  J. Cracowski,et al.  Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban , 2012, Thrombosis and Haemostasis.

[180]  A. Tripodi.  Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test? , 2011, Thrombosis and Haemostasis.

[181]  J. Tolstrup,et al.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study , 2011, Thrombosis and Haemostasis.

[182]  J. Healey,et al.  Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin , 2009, Circulation.

[183]  R. Winkle,et al.  The Use of Dabigatran Immediately After Atrial Fibrillation Ablation , 2012, Journal of cardiovascular electrophysiology.

[184]  I. Stiell,et al.  A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. , 2004, Journal of the American College of Cardiology.

[185]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[186]  P. Kamphuisen,et al.  Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.

[187]  G. Lip,et al.  Reliable Identification of “Truly Low” Thromboembolic Risk in Patients Initially Diagnosed With “Lone” Atrial Fibrillation: The Belgrade Atrial Fibrillation Study , 2012, Circulation. Arrhythmia and electrophysiology.

[188]  S. Yusuf,et al.  Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation , 2010, Circulation.

[189]  G. Lip,et al.  Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study , 2012, Circulation.

[190]  A. Russo,et al.  Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study): Six-Month Follow-Up Study , 2011, Circulation. Arrhythmia and electrophysiology.

[191]  David A Fitzmaurice,et al.  Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial , 2007, BMJ : British Medical Journal.

[192]  A. Camm,et al.  Atrial fibrillation: the rate versus rhythm management controversy. , 2012, The journal of the Royal College of Physicians of Edinburgh.

[193]  P. Kirchhof,et al.  Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) a , 2010, European heart journal.

[194]  E. Rahme,et al.  Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. , 2012, JAMA.

[195]  Hugh Calkins,et al.  Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. , 2011, Heart rhythm.

[196]  K. Stangl,et al.  Superiority of ibutilide (a new class III agent) overdl-sotalol in converting atrial flutter and atrial fibrillation , 1998, Heart.

[197]  H. Crijns,et al.  Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. , 2008, JAMA.

[198]  G. Breithardt,et al.  Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial Running title: Goette et al.; The ANTIPAF Trial , 2010 .

[199]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[200]  D. Singer,et al.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[201]  Stanley Nattel,et al.  Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. , 2012, The Canadian journal of cardiology.

[202]  G. Lip,et al.  Atrial fibrillation , 2012, The Lancet.